Advisor Pro analyzes patient data from continuous glucose monitoring, self-monitoring blood glucose and insulin pump devices to generate personalized insulin delivery recommendations. These recommendations are meant to help healthcare providers manage treatment for patients with Type 1 diabetes.
The FDA decision marks DreaMed Diabetes’ second regulatory approval this year. The company received the European Union’s CE Mark in February.
More articles on supply chain:
4 latest FDA approvals
Almost two-thirds of consumers think product recalls are just ‘red tape’
Flex Pharma to slash 60% of workforce, consider sale or merger
